Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Hydrochlorothiazide use and risk of Merkel cell carcinoma and malignant adnexal skin tumors: A nationwide case-control study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Factors associated with patient-reported importance of skin clearance among adults with psoriasis and atopic dermatitis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Estimating CDKN2A mutation carrier probability among global familial melanoma cases using GenoMELPREDICT

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Real-world drug survival of ixekizumab for psoriasis

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. A systematic review and meta-analysis of the regional and age-related differences in atopic dermatitis clinical characteristics

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Hydrochlorothiazide use has been associated with markedly increased risk of squamous cell carcinoma. No previous studies have investigated the association between hydrochlorothiazide use and the risk of Merkel cell carcinoma (MCC) and malignant adnexal skin tumors (MAST).

OBJECTIVE: To examine the association between hydrochlorothiazide use and the risk of MCC and MAST.

METHODS: Using Danish nationwide health registries, we identified all patients with incident MCC or MAST during 2004-2015 and matched cases individually to cancer-free population controls by risk set sampling. Using conditional logistic regression, we estimated odds ratios (ORs) associated with cumulative use of hydrochlorothiazide.

RESULTS: The adjusted ORs for MCC and MAST associated with high use (≥50,000 mg) of hydrochlorothiazide was 2.3 (95% CI, 1.1-4.8) and 3.6 (95% CI, 1.9-7.0), respectively, increasing to 3.3 (95% CI 1.3-8.3) and 5.6 (95% CI 2.4-13.3) with highest use (≥100,000mg). We found no increase in risk of the tumors in analyses of drugs with similar indications as hydrochlorothiazide, except a tendency toward an increased risk of MCC associated with use of furosemide (OR 1.9, 95% CI 0.9-4.0).

LIMITATIONS: No data on sun exposure was available.

CONCLUSIONS: Hydrochlorothiazide use is associated with an increased risk of MCC and MAST.

Original languageEnglish
JournalJournal of the American Academy of Dermatology
Volume80
Issue number2
Pages (from-to)460-465
Number of pages6
ISSN0190-9622
DOIs
Publication statusPublished - 15 Feb 2019

ID: 55578625